Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

 (Currently amended) An <u>isolated</u> antibody that comprises at least one amino acid sequence as listed in SEQ ID NOs:1-8 <u>comprising</u>

a V_{H} domain having a CDR1 comprising the sequence set forth in SEQ ID NO:6, a CDR2 comprising the sequence set forth in SEQ ID NO:7, and a CDR3 comprising the sequence set forth in SEQ ID NO:8; and

a V_L domain having a CDR1 comprising the sequence set forth in SEQ ID NO:3, a CDR2 comprising the sequence set forth in SEQ ID NO:4, and a CDR3 comprising the sequence set forth in SEQ ID NO:5.

wherein the antibody which can bind to Factor IX/Factor IXa and increase the procoagulation activity of FIXa Factor IXa.

- 2-7. (Canceled)
- (Currently amended) The <u>isolated</u> antibody according to claim <u>1</u> 7, wherein the antibody <u>V_H domain comprises the sequence set forth in SEQ ID NO: 1 and the V₁ domain comprises the sequence set forth in SEQ ID NO:2.
 </u>
- (Currently amended) The <u>isolated</u> antibody according to claim 1, which wherein the antibody is an IgG-antibody.
- (Currently amended) The <u>isolated</u> antibody according to claim 1, which wherein the antibody is a monoclonal antibody.
- (Currently amended) The <u>isolated</u> antibody according to claim 1, which wherein the antibody is an antibody fragment.

Appl. No. 10/661,366 Amdt. dated February 21, 2007 Reply to Office Action of August 24, 2006

- (Currently amended) The <u>isolated</u> antibody according to claim 1, which wherein the antibody is a recombinant antibody.
- (Currently amended) The <u>isolated</u> antibody according to claim 12, which wherein the antibody is a single chain antibody.
- (Currently amended) The <u>isolated</u> antibody according to claim 1, which wherein the antibody is a humanized antibody.
- $10. \qquad \hbox{(Currently amended) The } \underline{isolated} \ antibody \ of claim \ 1, \ wherein \ the \\ antibody \ is labeled.$
 - 11-21. (Canceled)
- 22. (Currently amended) A pharmaceutical composition comprising an isolated antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.
- 23. (Currently amended) The pharmaceutical composition <u>comprising the</u>
 <u>isolated antibody</u> of claim <u>8 22</u>, wherein the antibody comprises at least one complement
 determining region (CDR), the at least one CDR comprising at least one amino acid sequence as
 listed in SEO ID NOs:3-8.
- (Currently amended) The pharmaceutical composition according to claim
 further comprising a Factor selected from the group consisting of factor Factor IX, factor
 Factor IXaα IXa, factor FactorIXaβ IXa, and/or factor Factor FX, and combinations thereof.
 - 25-27. (Canceled)
- 28. (New) The pharmaceutical composition according to claim 22, further comprising a Factor selected from the group consisting of Factor IX, Factor IXa α , Factor IXa β , and combinations thereof.